The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes).
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31535299.
- Also identified by DOI 10.1245/s10434-019-07830-w.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Management of regional lymph nodes in patients with melanoma has evolved significantly in recent years. The value of nodal intervention, long utilized for its perceived therapeutic benefit, has now shifted to that of a critical prognostic procedure used to guide clinical decision making. This review focuses on the three landmark, randomized controlled trials evaluating the role of surgery for regional lymph nodes in melanoma: Multicenter Selective Lymphadenectomy Trial I (MSLT-I), German Dermatologic Cooperative Oncology Group-Selective Lymphadenectomy Trial (DeCOG-SLT), and Multicenter Selective Lymphadenectomy Trial II (MSLT-II).
Medical subject headings
- Lymph Node Excision
- Lymph Nodes
- Melanoma
- Patient Selection